Panagora Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Panagora Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,507	Closed	-$82.4K	–	1241
2024 Q2	$82.4K	Sell	11,507 -15,258	-57%	-$132K	﹤0.01%	1167
2024 Q1	$232K	Buy	+26,765	New	+$181K	﹤0.01%	1126
2021 Q3	–	Sell	-430	Closed	-$18K	–	2121
2021 Q2	$18K	Buy	+430	New	+$16.7K	﹤0.01%	2182

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Panagora Asset Management's MRVI Position: Q3 2024 in Review

Panagora Asset Management sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 11,507 shares — an estimated $82.4K sold.

Panagora Asset Management first reported a position in MRVI in Q2 2021 and held it in 3 quarters. The position peaked at $232K in Q1 2024. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Panagora Asset Management reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Panagora Asset Management sold 11,507 Maravai LifeSciences shares in Q3 2024, an estimated $82.4K.
Panagora Asset Management first reported a position in Maravai LifeSciences in Q2 2021 and held it in 3 quarters.
Panagora Asset Management's Maravai LifeSciences position peaked at $232K in Q1 2024.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Panagora Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.